Top Markets
#1 Nesa Nesa +802.33%
#2 Cortex Cortex +68.77%
#3 Kinesis Silver Kinesis Silver +55.82%
#4 Merlin's Seal BTC Merlin's Seal BTC +45.67%
#5 QuantixAI QuantixAI +24.00%
#6 EXOD EXOD +22.78%
#7 Cash Cat Cash Cat +21.46%
#8 OpenEden OpenEden +17.35%
#9 Instadapp Instadapp +16.92%
#10 Alchemist AI Alchemist AI +14.61%
Coin of the day
Nesa Nesa
Settings
Language
ENGLISH
Currency
USD
Theme
Shenzhen Salubris Pharmaceuticals Co., Ltd. Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd.

002294
Rank in Stocks #3532
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Share Price
$4.64
Market Cap
$5.17B
Change (1 day)
0.34%
Change (1 year)
-37.46%
Country
CN
Trade Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)

Category

Healthcare
Revenue for Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Revenue in Aug 2026 TTM: 0
According to Shenzhen Salubris Pharmaceuticals Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Shenzhen Salubris Pharmaceuticals Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Intuitive Surgical, Inc. Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
ISRG.US
 $11.03B -
US
EssilorLuxottica S.A. EssilorLuxottica S.A.
EssilorLuxottica S.A.
EL.PA
 $34.74B -
FR
HOYA Corporation HOYA Corporation
HOYA Corporation
7741.T
 - -
JP
Becton, Dickinson and Company Becton, Dickinson and Company
Becton, Dickinson and Company
BDX.US
 $20.84B -
US
Alcon Inc. Alcon Inc.
Alcon Inc.
ALC.SW
 - -
CH